$BMY

Haller Julia A sold 3,800 shares of BRISTOL MYERS SQUIBB CO (BMY) at $63.31 ($0.24M total) on 2026-11-05.

Bristol Myers Squibb's Camzyos showed consistent efficacy and safety in a 56-week Phase 3 trial for pediatric patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). No patient had left ventricular ejection fraction fall below 50%. The trial included a 28-week placebo-controlled period and demonstrated significant reductions in Valsalva left ventricular outflow tract gradient. Additional data will be presented at the American Heart Association’s Scientific Sessions 2026.

Bristol Myers Squibb (BMY) has a 4.08% yield, with shares up 40.82% in a year. The company expects 2026 EPS of $6.35-$6.55, covering its $2.52 annual dividend. Debt is $44.81B, down from $51.2B in 2024. Eliquis revenue may drop by $1.5B-$2B in 2027. BMY's dividend has increased for 17 consecutive years, with a payout ratio near 40%.

FDA accepted uniQure's Huntington disease gene therapy application, with a decision expected in May 2027. AV-1959R (Nuravax) received fast track designation for Alzheimer's prevention. FDA decisions are pending on Bayer's asundexian and Regeneron's cemdisiran. Bristol Myers Squibb reported a patient death in MS trials. Novartis' remibrutinib showed relapse rate reductions in MS trials but no significant disability progression impact.

Microsoft loses CVP Mazhar Mohammed to AWS, gains Chad Thompson from Alteryx. Amazon appoints Gail Carpenter as CFO of Global Entertainment and Advertising. Lila Bio, a biotech startup, names Kimberly Ma as CDO. BECU appoints Geoffrey Fonga as VP of AI transformation. RevealDx, developing AI for cancer detection, adds two leaders. LogicGate, a software company, names two new leaders. Known, an AI accountability infrastructure company, appoints Edna Conway to its advisory council.

The FDA approved Bristol Myers Squibb's CAMZYOS (mavacamten) for symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults and pediatric patients weighing 30 kg or more. The approval follows positive results from the SCOUT-HCM trial, showing significant reductions in LVOT gradient and symptom improvements. CAMZYOS is the first FDA-approved therapy for pediatric oHCM.

Bristol Myers Squibb (BMY) stock rose 42.9% in the past year. Management warned of a $1.5B-$2B revenue drop for Eliquis in 2027 due to lost exclusivity in Europe. Eliquis generated $14.4B in 2025, 30% of total revenue. Growth medicines revenue increased 12% in Q3 2026. The stock trades at 13.9x earnings, below the S&P 500's 22.8x.

Genentech/Roche's investigational drug divarasib showed improved overall survival and progression-free survival in KRAS G12C-mutated NSCLC patients compared to standard treatments sotorasib (Amgen) and adagrasib (Bristol Myers Squibb). The phase 3 Krascendo 1 trial results, presented at ESMO Congress, indicated a 44% lower risk of death with divarasib, along with fewer severe adverse effects.

Bristol-Myers Squibb (BMY) reported Q3 growth driven by its eight billion-dollar medicines, including Breyanzi and Camzyos. New FDA approvals and pipeline advancements, such as Symvexis and admilparant, were highlighted. Despite revenue growth, margins fell due to increased R&D spending and launch costs. The company plans significant U.S. manufacturing investments. Management expects future growth from new launches and pipeline progress but notes near-term margin pressure.

Anthropic's AI, Claude, is being used by pharmaceutical companies to accelerate drug development. Generate Biomedicines reported a 70% reduction in CAR T-cell component length, while Divergence Labs and BigHat Biosciences also saw improvements in their research. Anthropic partnered with Bristol Myers Squibb to predict clinical trial success, with the AI reducing analysis time significantly.